Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. - Wikidata - awgldk - TriplyDB

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.

http://www.wikidata.org/entity/Q33394464

about

Alemtuzumab for multiple sclerosis Alemtuzumab for patients with chronic lymphocytic leukaemia Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use Need for a paradigm shift in therapeutic approaches to CNS injury Alemtuzumab for Multiple Sclerosis.Alemtuzumab for the treatment of multiple sclerosis Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety.Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.Potential role of immunoglobulin replacement therapy on MRI measures in multiple sclerosis: a systematic review.Alemtuzumab in multiple sclerosis: latest evidence and clinical prospects.Efficacy and safety of alemtuzumab in multiple sclerosis and impact on nursing role.Safety of monoclonal antibodies for the treatment of multiple sclerosis.Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional study Future MS care: a consensus statement of the MS in the 21st Century Steering Group.Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.Natural killer cells and their receptors in multiple sclerosis.Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone.Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.Current and future therapies for multiple sclerosis.Postarrest stalling rather than crawling favors CD8(+) over CD4(+) T-cell migration across the blood-brain barrier under flow in vitro.Novel treatment for immune neuropathies on the horizon.Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents.Drugs in development for relapsing multiple sclerosis.Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.Current evaluation of alemtuzumab in multiple sclerosis.Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis.Drug safety evaluation of alemtuzumab for multiple sclerosis.Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives.Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.Alemtuzumab in multiple sclerosis: an update.Monoclonal Antibodies for Relapsing Multiple Sclerosis: A Review of Recently Marketed and Late-Stage Agents.Intervening to reduce the risk of future disability from multiple sclerosis: are we there yet?Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis.Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials.Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study.

P2860

Q24185899-84448A66-8800-4FCC-8843-51C28506BFCC Q24203628-6955BEB1-9AC4-4356-A399-FAC965AC532F Q26800128-1372C963-DCE8-45CE-B2DF-929FE1D7E7FA Q26849781-D7FAA8F6-3BB5-4F12-B4CB-C621FCAE059C Q27025042-30018D0B-EBEC-4261-8AD3-2760ED81BB11 Q28069730-688036E0-4530-4DBC-ACEC-56FB85C7785F Q28080506-E18FE776-040D-4689-9B0B-7F4A2F83BFBB Q30458930-08E42154-3D4F-47AD-B22E-19C41E4F7BE9 Q30490389-0743C7A0-CC68-457B-ABF7-87CF30C2F560 Q31009149-A90501FF-5FAF-4504-AF6D-CCC51800079E Q33407411-C61C2179-1403-44E8-A543-20D49B33ECEE Q33412834-16759F59-EFC0-47DF-991D-B0576BAEAE86 Q34542922-FA49AB39-50B5-4670-BA92-3D1B4AE2282C Q34926430-122C6594-3819-46A5-A928-225D6E8B5948 Q36592674-E43A37BE-52DC-4705-ACA3-15F79AAD05DA Q36672726-309A7C96-14F5-4525-8048-35C9CBDB4F32 Q37124504-130A476C-3EA1-46AC-819B-CC7AB20E669A Q37200093-A65787DF-A478-48F4-91E7-E47130251D3D Q37253834-9773A5E7-293A-4534-A6FC-DB1273E0DC95 Q37287769-4F3C4385-18C2-4390-825F-AD98D8763429 Q37420442-76CEC51F-31B7-4040-9D0A-B87DAA57A5B9 Q37892641-AE52095E-ACC5-4143-8AEA-DC15BA6A1B64 Q38051577-CFEFEDF0-4604-4171-8285-CE5D85DB56DD Q38101004-DA135E07-1B94-4A2E-BECE-401B7FB96B9C Q38107524-1B07CCEB-ABD7-46B8-8826-6D28358AD7EA Q38167350-00924033-5B9B-43FF-91B1-FA49C40212FC Q38172961-CBF0705D-6E53-48D0-9EB4-BBFA2535B0F8 Q38173374-05F21BC5-26D8-49CB-9D3C-565B05911A54 Q38220740-76F61FE2-0813-43E4-8C7A-7B3B27A52A94 Q38262622-F28719C4-5A5D-4D58-A9EA-8A435E6C2CAC Q38364547-149D874A-6D00-4853-9E97-A5C8AE1EE49B Q38371740-5AD866E6-B602-4394-A892-67DCBEE502E3 Q38536770-FAAF216D-B055-47A8-8E43-F3969949C8AE Q38747100-D3611ACD-CE72-4FB8-8706-6D1094A5CBE3 Q38777286-5E83EAC4-3571-489B-89E6-889532D5168A Q38911206-D87D43CB-1213-46AB-B631-CAD04AECA728 Q40412270-DE9EBD53-B766-4651-8267-19D4BC4C7F33 Q41010737-1304FBCD-F858-44BB-9364-4444C885C26D Q41197212-7832B73C-459B-4596-BEA3-E9577F083E45 Q44601099-22636097-FF16-4BAB-8D7C-8B1607A15A95

P2860

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.

http://www.wikidata.org/entity/Q33394464

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Alemtuzumab versus interferon ...... of clinical efficacy outcomes.

@ast

Alemtuzumab versus interferon ...... of clinical efficacy outcomes.

@en

type

label

Alemtuzumab versus interferon ...... of clinical efficacy outcomes.

@ast

Alemtuzumab versus interferon ...... of clinical efficacy outcomes.

@en

prefLabel

Alemtuzumab versus interferon ...... of clinical efficacy outcomes.

@ast

Alemtuzumab versus interferon ...... of clinical efficacy outcomes.

@en

P1433

Q33394464-BA1BA39A-BFAA-4DF5-A677-FEBD854150B0

P1476

Q33394464-EDBBA0B6-67FE-4CAC-82B5-B0DDF906F353

P2093

Q33394464-2843B946-82E3-4C3E-B730-A145310C601D

Q33394464-3B2488D3-DBD0-47E3-9ABA-41844F425E48

Q33394464-43AFAEF8-EB14-4A20-A298-2F94C01208E8

Q33394464-493E01A6-9F9B-4A02-BBFF-65CEF9FDA718

Q33394464-526DE574-C4C9-4438-9C9F-E7EE0E224E5B

Q33394464-750FF9EC-F19F-44A0-9102-01AB0675E06D

Q33394464-7EED5CC2-4C88-4F81-BDEB-3AAB57B11D0E

Q33394464-9C2DA7DA-BB02-4982-A0CD-4D45D9326B21

Q33394464-AAA0D06F-AF69-4205-9D33-C880709075D0

Q33394464-AE1711E2-3835-4A87-819F-7186141DD9D5

P304

Q33394464-A197D068-7C81-4E5D-BD75-5091ACEE7570

P31

Q33394464-00E8C256-CBA1-4DE1-8704-179B50314BAF

P356

Q33394464-486EC9C5-06FD-4389-9A23-2CEF6BEF9042

P433

Q33394464-2A990BC6-021E-4309-AD6C-4076A0990D2A

P478

Q33394464-E38EC4A7-0C8D-44EA-AC72-CD9029C9A146

P50

Q33394464-9436FEBC-66A2-4B1C-997A-3E708056E3FC

P577

Q33394464-C80FA409-54F2-4B5A-A62F-D1291C8601D5

P698

Q33394464-31E4D025-A99D-4EBE-B8D1-076F52F73823

P921

Q33394464-64806523-3EAB-403D-9E95-2D3ADA730CF4

Q33394464-A9CCA044-85EF-40B2-BCB8-7C421AEDE088

P356

S1474-4422(11)70020-5

P1433

Lancet Neurology

P1476

Alemtuzumab versus interferon ...... of clinical efficacy outcomes.

@en

P2093

Alasdair J Coles

http://www.w3.org/2001/XMLSchema#string

Ann Doan-Do Bass

http://www.w3.org/2001/XMLSchema#string

Anton Vladic

http://www.w3.org/2001/XMLSchema#string

D Alastair S Compston

http://www.w3.org/2001/XMLSchema#string

Daniel R Wynn

http://www.w3.org/2001/XMLSchema#string

David H Margolin

http://www.w3.org/2001/XMLSchema#string

Edward Fox

http://www.w3.org/2001/XMLSchema#string

Jeffrey Palmer

http://www.w3.org/2001/XMLSchema#string

M Shelton Smith

http://www.w3.org/2001/XMLSchema#string

Stephen L Lake

http://www.w3.org/2001/XMLSchema#string

P304

338-348

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1474-4422(11)70020-5

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Krzysztof Selmaj

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21397567

http://www.w3.org/2001/XMLSchema#string

P921

relapsing-remitting multiple sclerosis

multiple sclerosis